Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVEDERM VOLUME XC for temple hollowing. Following its U.S. FDA approval in March 2024, JUVEDERM VOLUMA XC is the first and only hyaluronic acid filler approved to treat moderate to severe temple hollowing in adults over 21. The JUVEDERM(R) Collection of Fillers is the number one chosen HA dermal filler brand by patients and providers, and now offers the largest range of treatment indications to meet patients’ aesthetic goals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Wolfe Research starts Incyte at Outperform amid ‘major push’ in I&I
- AbbVie submits BLA for Teliso-V in NSCLC with c-Met protein overexpression
- AbbVie’s tavapadon meets primary endpoint in Phase 3 Parkinson’s trial
- AbbVie reports ‘positive’ results from Measure Up 1, Measure Up 2 Phase 3 trials
- AbbVie receives positive CHMP opinion for mirvetuximab soravtansine